missing translation for 'onlineSavingsMsg'
Learn More

CD262 (DR5) Monoclonal Antibody (DJR2-4 (7-8)), Biotin, eBioscience™, Invitrogen™

Mouse Monoclonal Antibody

Marke:  Affymetrix eBioscience 13-9908-82

237.34 CHF gültig bis 2024-03-29
Benutzen Sie den Promotions-Code "21615" um Ihren Promotions-Preis zu erhalten.



Additional Details : Gewicht : 0.25000kg

 Lernen Sie weitere Varianten dieses

Artikelnummer. 15330110

  • 356.00 CHF / 100 Mikrogramm
Verfügbar ab: 08-05-2024
Sie sich ein, um den Lagerbestand zu sehen
Zum Warenkorb hinzufügen

Beschreibung

Beschreibung

Description: The DJR2-4 monoclonal antibody reacts with human DR5, also known as TRAIL-R2, Apo2, TRICK2 and KILLER. DR5 binds to TRAIL, activates NF-kappaB, and induces TRAIL-mediated apoptosis. DR5 is expressed broadly by normal tissues as well as several tumor cells. Applications Reported: The DJR2-4 (a.k.a. 7-8) antibody has been reported for use in flow cytometric analysis. Applications Tested: The DJR2-4 (a.k.a. 7-8) antibody has been tested by flow cytometric analysis of human MOLT-4 cell line and human DR5-transfected cells. This can be used at less than or equal to 0.5 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Filtration: 0.2 μm post-manufacturing filtered.

DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a recently identified death domain containing receptor for TRAIL, which mediates TRAIL induced apoptosis. DR5 is a member of the TNF-receptor superfamily, and contains an intracellular death domain. DR5 can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by DR5. Two transcript variants encoding different isoforms of DR5 and one non-coding transcript have been found. Overexpression of DR5 induces apoptosis and activates NF-kappa-B. DR5 is expressed in a number of cell types, and to particularly high levels in lymphocytes and spleen. Diseases associated with DR5 dysfunction include squamous cell carcinoma, and diffuse infiltrative lymphocytosis syndrome.
Spezifikation

Spezifikation

CD262 (DR5)
Monoclonal
0.5 mg/mL
PBS with 0.09% sodium azide; pH 7.2
O14763
TNFRSF10B
Affinity chromatography
RUO
8795
4° C, store in dark, DO NOT FREEZE!
Liquid
Flow Cytometry
DJR2-4 (7-8)
Biotin
TNFRSF10B
apoptosis inducing protein TRICK2A/2B; apoptosis inducing receptor TRAIL-R2; CD262; cytotoxic TRAIL receptor-2; death domain containing receptor for TRAIL/Apo-2L; death receptor 5; Dr5; dr-5; Fas-like protein; KILLER; KILLER/DR5; KILLER/DR5 TRAIL death-inducing receptor; Ly98; MK; p53-regulated DNA damage-inducible cell death receptor(killer); sCD262; soluble CD262; TNF receptor superfamily member 10b; TNF-related apoptosis-inducing ligand receptor 2; TNFRSF10B; TRAIL receptor 2; TRAILR2; TRAIL-R2; TRICK2; TRICK2A; TRICK2B; TRICKB; tumor necrosis factor receptor superfamily member 10B; tumor necrosis factor receptor superfamily, member 10b; tumor necrosis factor receptor-like protein ZTNFR9; UNQ160/PRO186; ZTNFR9
Mouse
100 μg
Primary
Human
Antibody
IgG1 κ
Produktvorschläge

Produktvorschläge

Videos
Sicherheitsdatenblatt (SDS)
Dokumentation

Dokumentation

Zertifikate
Sonderangebote

Sonderangebote

For Research Use Only.